The Efficacy of Mirabegron for the Relief of Ureteral Stent-Related Symptoms

The Efficacy of Mirabegron for the Relief of Ureteral Stent-Related Symptoms

To investigate the efficacy of mirabegron for lower urinary tract symptoms in patients with an indwelling ureteral stent after ureterorenoscopic lithotripsy. This was a prospective follow-up study of 76 patients with stent-related symptoms (SRSs). Patients with upper urinary calculi who were pre-ste...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Acta medica Okayama 2020-04, Vol.74 (2), p.145-150
Hauptverfasser: Otsuki, Hideo, Yamasaki, Tomoya, Hori, Shunsuke, Aoki, Hiroshi, Kosaka, Takeo, Uehara, Shinya, Fujio, Kei
Format: Artikel
Sprache:eng
Schlagworte:
Acetanilides - administration & dosage
Adrenergic beta-3 Receptor Agonists - administration & dosage
Aged
Female
Humans
Lithotripsy
Male
Middle Aged
Prospective Studies
Quality of Life
Stents - adverse effects
Thiazoles - administration & dosage
Urinary Bladder, Overactive - drug therapy
Urinary Bladder, Overactive - etiology
Urinary Calculi - surgery
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To investigate the efficacy of mirabegron for lower urinary tract symptoms in patients with an indwelling ureteral stent after ureterorenoscopic lithotripsy. This was a prospective follow-up study of 76 patients with stent-related symptoms (SRSs). Patients with upper urinary calculi who were pre-stented for > 2 weeks before lithotripsy were examined for the presence of SRSs by tests including the International Prostate Symptom Score (IPSS), OAB Symptom Score (OABSS), and urinary bother and pain measured by a Visual Analogue Scale (VAS) before lithotripsy. Mirabegron (50 mg/day) was prescribed post-lithotripsy for 2 weeks. SRSs were assessed at the time of stent removal. The IPSS scores improved significantly from 16.2 to 14.3 (p
ISSN:0386-300X
DOI:10.18926/AMO/58273